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OBJECTIVES We sought to assess survival among patients with diabetes and multivessel coronary artery
disease (MVD) after percutaneous coronary intervention (PCI) and after coronary artery
bypass grafting surgery (CABG).
BACKGROUND The Bypass Angioplasty Revascularization Investigation (BARI) demonstrated that diabetics
with MVD survive longer after initial CABG than after initial PCI. Other randomized trials
or observational databases have not conclusively reproduced this result.
METHODS A large, regional database was linked to the National Death Index to assess five-year
mortality. Of 7,159 consecutive patients with diabetes who underwent coronary revascular-
ization in northern New England during 1992 to 1996, 2,766 (38.6%) were similar to those
randomized in the BARI trial. Percutaneous coronary intervention was the initial revascu-
larization strategy in 736 patients and CABG in 2,030. Cox proportional hazards regression
was used to calculate risk-adjusted hazard ratios (HR) and 95% confidence intervals (CI
95%).
RESULTS Patients who underwent PCI were younger, had higher ejection fractions and less extensive
coronary disease. After adjusting for differences in baseline clinical characteristics, patients
with diabetes treated with PCI had significantly greater mortality relative to those undergoing
CABG (HR 5 1.49; CI 95%: 1.02 to 2.17; p 5 0.037). Mortality risk tended to increase
more among 1,251 patients with 3VD (HR 5 2.02; CI 95%: 1.04 to 3.91; p 5 0.038) than
among 1,515 patients with 2VD (HR 5 1.33; CI 95%: 0.84 to 2.1; p 5 0.21).
CONCLUSIONS In this analysis of a large regional contemporary database of patients with diabetes selected to
be similar to those enrolled in the BARI trial, five-year mortality was significantly increased
after initial PCI. This supports the BARI conclusion on initial revascularization of patients
with diabetes and MVD. (J Am Coll Cardiol 2001;37:1008–15) © 2001 by the American
College of Cardiology
Patients with diabetes mellitus have a higher risk of cardio-
vascular mortality than the general population (1,2). This
increase in risk is believed to be related to accelerated
coronary atherosclerosis, a higher frequency of complica-
tions of coronary disease, including myocardial infarction
(MI), as well as a higher likelihood of mortality resulting
from those complications (3).
Although only 5% of the population have diabetes; 13%
to 25% of the patients undergoing coronary revasculariza-
tion procedures have diabetes (4–8). Patients with diabetes
experience higher perioperative as well as midterm mortality
See page 1016
rates compared with nondiabetics undergoing coronary
artery bypass grafting (CABG) (9,10). However, patients
with diabetes have also been shown to have less favorable
long-term survival after percutaneous coronary intervention
(PCI) (4,11). Thus, for patients with diabetes requiring
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revascularization, the choice of procedure has provoked
much controversy.
The Bypass Angioplasty Revascularization Investigation
(BARI) trial demonstrated that, for patients with treated
diabetes mellitus and multivessel coronary artery disease
(MVD) who were candidates for either CABG or PCI,
initial CABG was associated with a markedly lower five-
year mortality rate relative to initial PCI (19.4% vs. 34.5%,
respectively, p 5 0.003) (6). This result triggered a National
Heart, Lung and Blood Institute (NHLBI) clinical alert
recommending bypass surgery in this patient group. How-
ever, this recommendation has not been fully accepted
(12,13) in part because the results of other randomized trials
have not been completely consistent with BARI.
Although the Coronary Angioplasty versus Bypass Re-
vascularization Investigation (CABRI) demonstrated
greater survival at two years in 122 patients with diabetes
undergoing CABG (14), the combined results of the Emory
Angioplasty versus Surgery Trial (EAST) (15), CABRI (16)
and the Randomized Intervention Treatment of Angina
(RITA) trial (17), which included 233 randomized patients
with diabetes, demonstrated similar five-year mortalities in
the patients treated with PCI (15%) and CABG (12%) (13).
Moreover, some have doubted that the BARI result can be
generalized to “real world” medical practice because diabetes
was not a prespecified subgroup for analysis (18), and the
BARI population with diabetes was relatively small and
highly selected (6).
The purpose of this analysis was to evaluate revascular-
ization strategies in patients with diabetes treated in our region.
A large regional registry of consecutive coronary revasculariza-
tion procedures was used to identify all patients with diabetes
and MVD requiring revascularization and to compare their
long-term survival after CABG versus PCI procedures.
METHODS
Data collection. Data were collected by the Northern New
England Cardiovascular Diseases Study Group—a volun-
tary, regional consortium of physicians, allied health profes-
sionals, administrators and scientists from the five institu-
tions in Maine, New Hampshire and Vermont, who are the
sole providers of CABG and PCI in the region, and one
Massachusetts-based hospital, who have banded together to
study the process and outcomes of their cardiovascular care.
Since 1987 this group has collected data prospectively on all
coronary revascularizations in the region. Details of the data
collection have previously been described (7,8). Briefly,
information was collected in the following categories: de-
mographics, past medical history, primary indication for
procedure, priority of procedure, therapy, cardiac anatomy
and function, procedural details and outcomes. Demo-
graphics included name, date of birth, gender and other
unique patient identifiers. Past medical history included
information on previous CABG, PCI and MI, the dates of
these events, cardiac risk factors and comorbid conditions,
including diabetes mellitus documented in the medical
record or by patient history, congestive heart failure (CHF),
chronic obstructive pulmonary disease (COPD), peripheral
vascular disease (PVD) and renal disease requiring dialysis.
Priority of the revascularization procedure was classified as
nonurgent, urgent and emergent. Priority was assessed by
the operator in the following fashion: emergent signified
that medical factors relating to the patient’s cardiac disease
dictated that the procedure be performed within hours to
prevent morbidity or death. Urgent signified that medical
factors required the patient to stay in the hospital for the
procedure before discharge. Nonurgent signified that med-
ical factors indicated the need for the procedure, but the
clinical situation allowed discharge from the hospital with
readmission at a later date. Cardiac catheterizations were
performed at the participating or referring institutions using
their own standard methods during the course of regular
clinical care. Coronary anatomy was assessed using local
standards. Patients were classified into those with two-
vessel coronary artery disease (2VD) and those with three-
vessel coronary artery disease (3VD) using methods adapted
from the NHBLI Coronary Artery Surgery study (19). Data
collection methods of the Northern New England Cardio-
vascular Disease Study Group have been approved by the
human subjects committees of each of the participating
institutions.
Patient population. A total of 7,159 patients with diabetes
underwent coronary revascularization procedures at the
member institutions of the Northern New England Cardio-
vascular Disease Study Group between January 1, 1992 and
December 31, 1996. This study examined the outcomes of
patients within this population with characteristics making
Abbreviations and Acronyms
BARI 5 Bypass Angioplasty Revascularization
Investigation
CABG 5 coronary artery bypass grafting
CABRI 5 Coronary Angioplasty versus Bypass
Revascularization Investigation
CHF 5 congestive heart failure
CI 95% 5 95% confidence interval
COPD 5 chronic obstructive pulmonary disease
EAST 5 Emory Angioplasty versus Surgery Trial
HR 5 hazard ratio
MAHI 5 Mid America Heart Institute
MI 5 myocardial infarction
MVD 5 multivessel coronary artery disease
NHLBI 5 National Heart, Lung and Blood Institute
PCI 5 percutaneous coronary intervention
PTCA 5 percutaneous transluminal coronary
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them similar to patients randomized in the BARI trial (Fig.
1). Patients were excluded if they: were $80 years of age,
had less than 2VD, had prior revascularization procedures,
had left main disease (.50% stenosis), had emergency
procedures or had experienced an acute MI within 24 h
before the procedure. The final study population consisted
of 2,766 patients with diabetes and MVD and clinical
indications for revascularization. Percutaneous coronary in-
tervention was performed on 736 of these patients, and
2,030 patients underwent CABG procedures.
Follow-up. The outcome measure of the study was all-
cause mortality over a five-year interval. Median follow-up
among 2,766 patients with diabetes was 1.8 years with
13.1% reaching four-year follow-up. Mortality through
December 31, 1996 was determined by a probabilistic
match of the regional registry to the National Death Index
(US Department of Health and Human Services) (20,21)
using some combination of name, social security number,
date of birth, gender, date last known alive and state of last
known residence. The accuracy of the National Death Index
is between 92% and 99%, depending on which identifiers
are available (22,23).
Procedures. Patients undergoing initial bypass surgery re-
ceived an average of 3.8 distal anastomoses. Ninety-one per-
cent of patients had an internal mammary graft placed. Among
patients undergoing initial PCI, a culprit lesion strategy pre-
dominated with intended incomplete revascularization (a
greater number of vessels with significant disease than were
intervened upon) in at least 74% of patients. Only 14% of PCI
patients received stents starting in 1994. Stent procedures
accounted for ,5% of total patient-years of follow-up. Abcix-
imab was used in only four patients, all in 1996.
Statistical analysis. Baseline characteristics were summa-
rized with mean values for continuous variables and per-
centages for discrete variables. Patients were assigned a
treatment variable according to their initial revascularization
procedure (either PCI or CABG). Comparisons of charac-
teristics between the PCI and CABG groups were made
using the t test for continuous variables and the chi-square
test for categorical variables. Prior analyses of the CABG
and PCI database indicate that the most important comor-
bid conditions affecting outcome were COPD, renal failure
requiring dialysis, PVD and diabetes. Other comorbid
conditions including dementia, chronic liver disease/
cirrhosis, peptic ulcer disease and cancer either did not
importantly influence outcome or occurred too infrequently
in the population to have an important effect (24,25).
Kaplan-Meier techniques were used to display the survivor-
ship function. A proportional hazard regression model was
used to assess the influence of initial procedure on long-
term outcome, while adjusting for baseline characteristics.
Hazard ratios (HR) and 95% confidence intervals (CI 95%)
were calculated. The covariates included age, gender, left
ventricular ejection fraction, priority of procedure, presence
of renal failure, COPD and PVD. A combined analysis for
patients with MVD, adjusted for the proportion of 3VD,
was performed. Analyses were also conducted separately for
patients with 2VD and 3VD.
A history of prior CHF has been demonstrated to be a
predictor of in-hospital mortality among patients undergo-
ing PCI (24) as well as a predictor of 30-day mortality after
CABG (25). Reliable collection of this information among
northern New England patients undergoing CABG began
in 1994 and, therefore, was not available for use in the
combined PCI-CABG dataset from 1992 to 1996, upon
which this study is based. In order to assess the potential
confounding impact of prior CHF on the results, a separate
analysis of 1,849 patients undergoing procedures from 1994
to 1996 was performed with CHF included as an adjust-
ment variable.
RESULTS
Baseline characteristics. Clinical, angiographic, hemody-
namic and procedural variables for patients with diabetes
undergoing initial CABG and PCI are compared in Table
Table 1. Baseline Characteristics of Diabetic Patients
PCI
n 5 736
CABG
n 5 2,030
Age (mean) 62.9 64.4*
Female (%) 45.2 35.7*
PVD (%) 18.1 20.7
COPD (%) 9.8 12.5†
Renal failure (%) 4.8 3.2
Nonurgent (mean %) 35.4 40.6†
Ejection fraction (%) 52.0 50.3†
Three-vessel disease (%) 15.9 55.9*
*p , 0.001 and †p , 0.05 (PCI compared with CABG).
CABG 5 coronary artery bypass grafting; COPD 5 chronic obstructive pulmo-
nary disease; PCI 5 percutaneous coronary intervention; PVD 5 peripheral vascular
disease.Figure 1. A total of 7,159 diabetic patients underwent coronary revascular-
ization procedures between January 1, 1992 and December 31, 1996. Patients
were excluded if they: were $80 years of age, had less than two-vessel disease,
had undergone prior PCI or CABG, had left main disease ($50% stenosis),
had emergency procedures or had experienced an acute MI within 24 h before
the procedure. The final study population consisted of 2,766 patients with
diabetes and MVD and clinical indications for revascularization. Percutaneous
intervention was performed on 736 of these patients, and 2,030 patients
underwent CABG procedures. CABG 5 coronary artery bypass grafting;
MI 5 myocardial infarction; MVD 5 multivesssel coronary artery disease;
PCI 5 percutaneous coronary intervention.
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1. Patients with diabetes undergoing PCI procedures were
younger and more likely to be women compared with those
undergoing CABG. Patients undergoing PCI were less
likely to have COPD. There was no statistically significant
difference in the proportion having PVD or renal failure.
Although PCI procedures were less likely to be nonurgent
compared with CABG procedures, PCI patients had better
left ventricular function as measured by ejection fraction.
The most conspicuous difference between the PCI and
CABG treated patients was in the extent of coronary artery
disease. Fifty-six percent of CABG treated patients had
3VD compared with 16% of PCI treated patients.
Adjusted survival outcomes. During 5,659 patient-years
of follow-up, 288 patients in the cohort died, 94 in the PCI
group died, and 194 in the bypass surgery group died. Death
rates per 100 patient-years were: 5.1 overall, 5.9 for the PCI
group and 4.8 for the bypass surgery group (Table 2).
Adjusted in-hospital mortality was similar for PCI and
bypass surgery patients: 2.1% and 2.6%, respectively. The
five-year Kaplan-Meyer survival was examined according to
revascularization strategy after adjusting for differences in
baseline characteristics (age, gender, ejection fraction, left
ventricular end-diastolic pressure, procedural priority and
comorbid conditions: COPD on bronchodilator therapy,
renal failure on dialysis or PVD). Survival in the two groups
was similar through the first three to four months (Fig. 2).
Thereafter, the curves separate and remain so throughout
the five-year follow-up period. After adjustment, patients
with diabetes undergoing initial PCI were 49% more likely
to die during follow-up compared with patients undergoing
initial bypass surgery (HR 5 1.49; CI 95%: 1.02 to 2.17;
p 5 0.037). When the analysis was repeated on the
subgroup of patients undergoing procedures from 1994 to
1996 and CHF was included as an adjustment variable, the
results did not change (HR for initial PCI 5 1.68; CI 95%:
1.08 to 2.62; p 5 0.02).
The five-year adjusted survival for patients with diabetes
with 2VD and 3VD revascularized initially with CABG or
PCI is shown in Figure 3. Among the 1,251 patients with
diabetes and 3VD, mortality risk more than doubled after
initial PCI compared with initial surgery, with an HR of
2.02 (CI 95%: 1.04 to 3.91; p 5 0.038). Mortality was also
higher after PCI among 1,515 patients with diabetes with
2VD with an HR of 1.33 (CI 95%: 0.84 to 2.1; p 5 0.2).
Although patients with 2VD appeared to benefit less from
initial PCI than those with 3VD, there was no statistically
significant interaction between the number of diseased
vessels and procedure that predicted survival.
DISCUSSION
This study used a large regional database to compare
five-year, all-cause mortality among patients with diabetes
Figure 2. Five-year Kaplan-Meyer survival according to revascularization strategy after adjusting for differences in baseline characteristics: age, gender,
ejection fraction, left ventricular end-diastolic pressure, procedural priority, comorbid conditions (chronic obstructive pulmonary disease requiring
bronchodilator therapy, renal failure on dialysis or peripheral vascular disease) and the proportion of patients with three-vessel disease. CABG 5 coronary
artery bypass grafting; HR 5 hazard ratio; PCI 5 percutaneous coronary intervention.
Table 2. Crude Five-year Mortality
Overall PCI CABG
Patient-years of follow-up 5,659 1,593 4,066
Number of deaths (total) 288 94 194
Death rate per 100 patient-years 5.1 5.9 4.8
CABG 5 coronary artery bypass grafting; PCI 5 percutaneous coronary intervention.
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and MVD undergoing initial PCI or CABG in northern
New England. After considering BARI entry requirements,
the analysis revealed that patients with diabetes undergoing
PCI are younger, more often women, have fewer comorbid
conditions, better left ventricular function and significantly
less extensive coronary artery disease. After adjustment for
these differences in baseline characteristics, initial PCI was
associated with a substantially worse five-year survival.
Comparison with previous studies. The BARI trial dem-
onstrated that the subgroup of patients with diabetes and
MVD had better long-term survival after initial CABG
compared with initial PCI (6,26). However, analyses of
other randomized trials (14–17) have not uniformly con-
firmed this result. Disparate findings among randomized
trials may relate to differences in patient populations. Such
differences may be magnified when the relatively smaller
diabetic groups are considered. In the absence of additional
prospective randomized trial data, investigators have turned
to analyses of diabetic cohorts within large registry databases
to confirm the BARI results.
Results from three single-institution databases (Duke [5],
Emory [27] and the Mid America Heart Institute [MAHI]
[28]), as well as the BARI registry analysis of “randomiz-
able” but “nonrandomized” patients (29), have previously
been reported. Hazard ratios (and CI 95%) for PCI treat-
ment compared with CABG among patients with diabetes
and MVD estimated from these reports are presented in
Figure 4. In all of these studies, patients similar to the
population with diabetes in BARI were selected, and
multivariate adjustment techniques were used to control for
confounding. In the Duke analysis, diabetes was associated
with a worse long-term outcome regardless of treatment
strategy; however, outcomes for patients with diabetes
treated with PCI versus CABG were not significantly
different. In the MAHI study, unadjusted survival tended to
be better in patients treated with CABG. However, after
adjustment for completeness of revascularization, the revas-
cularization method did not influence late mortality. Anal-
ysis of all patients with diabetes in the Emory database
showed no significant difference in five-year survival among
patients with diabetes after PCI or CABG, except in the
insulin-requiring patients whose outcomes were signifi-
cantly improved after CABG. In the BARI registry, ad-
justed five-year survival among 299 treated patients with
diabetes tended to be better after initial CABG; however,
this difference did not reach statistical significance. Al-
though none of the single-institution studies nor the BARI
registry showed a clear difference in survival for CABG
compared with PCI, this study demonstrated a significant
improvement in survival with initial CABG with an HR
approaching that seen in the BARI randomized trial
(Northern New England 5 1.49; BARI trial 5 1.78). What
should not be overlooked, however, is that the direction of
Figure 3. Five-year Kaplan-Meyer survival for 1,251 patients with diabetes and three-vessel disease and 1,515 with diabetes and two-vessel disease
revascularized initially with CABG or PCI after adjusting for differences in baseline characteristics (age, gender, ejection fraction, left ventricular
end-diastolic pressure, procedural priority and comorbid conditions: chronic obstructive pulmonary disease requiring bronchodilator therapy, renal failure
on dialysis or peripheral vascular disease). CABG 5 coronary artery bypass grafting; HR 5 hazard ratio; PCI 5 percutaneous coronary intervention.
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the benefit in all studies favors CABG over PCI with
overlapping confidence intervals (Fig. 4).
Severity of coronary disease. The severity of coronary
artery disease may be a particularly important determinant
of long-term survival in patients with diabetes depending
upon the revascularization approach. It has been suggested
that, unlike CABG, long-term outcome after PCI in
patients with diabetes is particularly unfavorable when
extensive disease is present at the time of the initial
procedure (30). Indeed, as shown in the table accompanying
Figure 4, when selection of the revascularization procedure
is based on physician/patient choice rather than random
assignment, there is a strong tendency to refer those with
more extensive disease (i.e., 3VD) to CABG. This practice
is supported by data from NHLBI Percutaneous Translu-
minal Coronary Angioplasty (PTCA) Registry (4) as well as
the Emory PTCA database (11), which demonstrate more
favorable survival after PTCA among patients with rela-
tively less extensive disease. The results of this analysis also
lend support to this practice. Among patients with 3VD,
the HR was 2.02 favoring CABG, and the survival curves
separated early, suggesting that even in the short term PCI
does not palliate extensive coronary disease as effectively as
bypass surgery. However, among patients with less extensive
disease (i.e., 2VD), PCI is nearly as effective as surgery in
the short term, and the difference between the five-year
survivals does not reach statistical significance.
Completeness of revascularization. Long-term survival
may also be effected by completeness of revascularization.
Others have shown that complete revascularization is ac-
complished more often with CABG than it is with PCI
(27), and, indeed, when incomplete revascularization is
accounted for, mode of revascularization does not correlate
with late mortality (11). Although in this study complete-
ness of revascularization could not be examined rigorously,
the data are consistent with previous reports in that at least
74% of PCI patients were incompletely revascularized,
reflecting a predominant strategy of “culprit lesion angio-
plasty,” whereas CABG procedures in this population av-
eraged 3.8 grafts per patient. From a practical standpoint,
the goal of this analysis was to compare revascularization
approaches in multivessel patients with diabetes as they are
practiced in northern New England. To accomplish this,
adjustment for completeness of revascularization was not
necessary. From a methodological standpoint, it may be
futile to attempt to separate the influence of “completeness
of revascularization” and “revascularization method” using
standard adjustment techniques if, indeed, there is strong
covariance between initial PCI and incompleteness of re-
vascularization.
Study limitations. This study has several limitations. First,
this is an observational study, and it is possible that one or
more unmeasured factors exist that effect outcome for which
we could not adjust. However, with respect to baseline
characteristics that are likely to predict long-term survival
after revascularization (age, number of diseased vessels,
ejection fraction and comorbid conditions), CABG treated
patients were generally sicker than PCI treated patients.
Figure 4. Hazard ratios (and 95% confidence intervals) at five- to six-year follow-up for initial PCI compared with CABG among patients with diabetes
and multivessel disease estimated from three single-institution database studies, the BARI registry, the current NNE and the BARI randomized trial. All
hazard ratios are adjusted except where indicated by asterisks. BARI 5 Bypass-Angioplasty Revascularization Investigation; CABG 5 coronary artery
bypass grafting; DM 5 diabetes mellitus; HR 5 hazard ratio; MAHI 5 Mid America Heart Institute; NNE 5 Northern New England database study;
PCI 5 percutaneous coronary intervention; 3VD 5 three-vessel disease.
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Thus, it is likely that more complete adjustment would tend
to further widen the difference between the CABG and PCI
survival curves. Second, unlike the BARI trial, there is no
certainty that all patients who underwent CABG were also
candidates for PCI and vice-versa. In fact, a substantial bias
toward CABG in patients with more extensive (3VD)
disease was apparent. Although it is possible that some
patients were, in fact, determined to be noncandidates for
either PCI or CABG, the extent to which such determina-
tions were based on differences in age, gender, left ventric-
ular function or comorbid conditions (PVD, COPD or
renal disease) was adjusted for in this analysis and, therefore,
should not confound the result. Third, 61% of the popula-
tion with diabetes was excluded from this analysis. Al-
though these exclusions might appear to limit the general-
izability of the findings, in fact, only patients in whom
clinical circumstances had an overriding influence on the
choice of revascularization approach were excluded. Pre-
sumably, in these patients the relative long-term benefits of
CABG versus PCI are less relevant. Fourth, we did not
collect data on treatment of diabetes, which also appears to
be an important determinant of mortality outcome after
revascularization. This information is now part of our data
collection. Although it is possible that our PCI patients had
more severe diabetes, this seems unlikely since they clearly
tended to have less severe coronary artery disease.
Further studies. While they cannot be examined in these
data, there are other areas of investigation which may
provide better understanding of the observed effect. For
example, more detailed assessment of coronary anatomy and
myocardial jeopardy by a core angiographic laboratory could
reveal anatomic substrates with less favorable outcomes after
PCI. Conversely, postprocedural protocols or patient com-
pliance may result in more successful cardiac risk factor
control after CABG. Examination of these issues must
await further studies.
Major technical advances in the field of percutaneous
coronary revascularization have occurred over the last several
years that may be particularly useful in improving outcomes
and restenosis rates in patients with diabetes, including
coronary stents (31), glycoprotein IIB/IIIA antiplatelet
agents (32) and gamma source radiation (33). Although
encouraging, proof that these modalities improve survival,
or indeed yield outcomes comparable with CABG surgery
in patients with diabetes, is lacking. Unfortunately, this
study cannot consider the impact of such novel technologies
on survival since patients treated with them accounted for
,5% of the total patient-years of follow-up. Further studies
must clarify this important issue. However, the results of
this analysis do support the contention that, for the patient
with diabetes and MVD who is a candidate for either
method of revascularization, “stand-alone” balloon angio-
plasty should not be considered an acceptable alternative to
CABG.
Conclusions. In summary, this large, regional prospective
study, which includes data on 2,766 patients with diabetes
undergoing their first coronary revascularization procedure,
indicates improved survival when CABG is the initial
revascularization approach. The analysis supports the rec-
ommendation of the initial NHLBI clinical alert that bypass
surgery is preferable to coronary angioplasty for the revas-
cularization of patients with diabetes with both 2VD- and
3VD.
Addendum
The participants in the Northern New England Cardiovas-
cular Disease Study Group are listed in a previous publica-
tion (34).
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